GCP
SVA

GSA Capital Partners’s Sinovac Biotech, Ltd SVA Stock Holding History

GSA Capital Partners’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-24,200
Closed -$155K – 2095
2016
Q1 		$155K Buy
24,200
+13,100
+118% +$78.7K 0.01% 1536
2015
Q4 		$63K Buy
+11,100
New +$59.7K ﹤0.01% 1764
2015
Q1 		– Sell
-13,186
Closed -$69K – 2366
2014
Q4 		$69K Sell
13,186
-51,614
-80% -$263K ﹤0.01% 1619
2014
Q3 		$312K Buy
64,800
+30,800
+91% +$165K 0.02% 1240
2014
Q2 		$192K Buy
+34,000
New +$207K 0.01% 1636

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GSA Capital Partners's SVA Position: Q2 2016 in Review

GSA Capital Partners sold out of Sinovac Biotech, Ltd (SVA) in Q2 2016, closing a stake of 24,200 shares — an estimated $155K sold.

GSA Capital Partners first reported a position in SVA in Q2 2014 and held it in 5 quarters. The position peaked at $312K in Q3 2014. 37 funds tracked by Wall St. Rank hold SVA as of Q2 2016.

  • GSA Capital Partners reported no remaining Sinovac Biotech, Ltd position as of Q2 2016 after selling out during the quarter.
  • GSA Capital Partners sold 24,200 Sinovac Biotech, Ltd shares in Q2 2016, an estimated $155K.
  • GSA Capital Partners first reported a position in Sinovac Biotech, Ltd in Q2 2014 and held it in 5 quarters.
  • GSA Capital Partners's Sinovac Biotech, Ltd position peaked at $312K in Q3 2014.
  • 37 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2016.

Based on GSA Capital Partners's 13F filing for Q2 2016, filed 4 Aug 2016.